TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07018206: Impact Of Upadacitinib On The Frequency Of Acute Recurrent Anterior Uveitis In Patients With Axial Spondyloarthritis

Sponsor: CARE ARTHRITIS LTD. · Phase: PHASE4 · Area: IMMUNOLOGY · Target Enrollment: 200 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$8,832,000

Rescue Site Savings

+$5,823,600

Unlock Full NCT07018206 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07018206 Rescue Dossier →